title: Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis.
abstract: A multi-site, masked, randomised parallel group study employing a double dummy treatment design was performed in canine veterinary patients to determine the comparative efficacy and safety of mavacoxib and carprofen in the treatment of pain and inflammation associated with osteoarthritis for a period of 134 days. Treatments were administered according to their respective summaries of product characteristics. Of 139 dogs screened, 124 were suitable for study participation: 62 of which were dosed with mavacoxib and 62 with carprofen. Both treatments resulted in a very similar pattern of considerable improvement as indicated in all parameters assessed by both owner and veterinarian. The primary efficacy endpoint 'overall improvement' was a composite score of owner assessments after approximately six weeks of treatment. Both drugs were remarkably effective, with 57/61 (93.4 per cent) of mavacoxib-treated dogs and 49/55 (89.1 per cent) of carprofen-treated dogs demonstrating overall improvement and with mavacoxib's efficacy being non-inferior to carprofen. The treatments had a similar safety profile as evidenced by documented adverse events and summaries of clinical pathology parameters. The positive clinical response to treatment along with the safety and dosing regimen of mavacoxib makes it an attractive therapy for canine osteoarthritis.
authors.affiliation: Chapel House, Lee, Ellesmere, Shropshire, SY12 9AF, UK.
authors.forename: M
authors.initials: M
authors.lastname: Payne-Johnson
authors.affiliation: Veterinary Medicine Research & Development Zoetis Inc, Mercuriusstraat 20, Zaventem B-1930, Belgium.
authors.forename: C
authors.initials: C
authors.lastname: Becskei
authors.affiliation: Veterinary Medicine Research & Development Zoetis Inc, Mercuriusstraat 20, Zaventem B-1930, Belgium.
authors.forename: Y
authors.initials: Y
authors.lastname: Chaudhry
authors.affiliation: Veterinary Medicine Research & Development Zoetis Inc, Mercuriusstraat 20, Zaventem B-1930, Belgium.
authors.forename: M R
authors.initials: MR
authors.lastname: Stegemann
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D002227:Carbazoles / Q000009:adverse effects / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004311:Double-Blind Method; D005260:Female; D007249:Inflammation / Q000188:drug therapy / Q000209:etiology / Q000662:veterinary; D008297:Male; D010003:Osteoarthritis / Q000150:complications / Q000188:drug therapy / Q000662:veterinary*; D010146:Pain / Q000188:drug therapy / Q000209:etiology / Q000662:veterinary; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D000096926:Benzenesulfonamides
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D002227:Carbazoles; D011720:Pyrazoles; C555097:4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; D000096926:Benzenesulfonamides; C007005:carprofen
keywords: Dogs; Non-steroidal anti-inflammatory drugs (NSAIDs); Osteoarthritis; Pain